Candel Therapeutics Shares Soar After FDA Fast Track of CAN-2409
December 12 2023 - 8:58AM
Dow Jones News
By Dean Seal
Shares of Candel Therapeutics surged after U.S. federal
regulators granted fast-track designation to its treatment for
pancreatic ductal adenocarcinoma.
The stock was up 58% at $1.37 in premarket trading. Shares had
fallen 51% year-to-date when the market closed Monday.
The clinical-stage biopharmaceutical company said Tuesday that
the U.S. Food and Drug Administration granted the designation for
CAN-2409, its lead investigational adenovirus asset, plus
valacyclovir as a treatment to improve overall survival in patients
with pancreatic ductal adenocarcinoma.
The FDA's fast-track designation facilitates development and
expedites the review of drugs that treat serious or
life-threatening conditions and fill unmet medical needs.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 12, 2023 08:43 ET (13:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Candel Therapeutics (NASDAQ:CADL)
Historical Stock Chart
From Apr 2024 to May 2024
Candel Therapeutics (NASDAQ:CADL)
Historical Stock Chart
From May 2023 to May 2024